Department Overview
The Hematopoietic Stem Cell Transplantation (HSCT) Department of Lu Daopei Hospital is one of the most active HSCT centres in the international, which has 162 air laminar flow rooms, and 1,556 beds. There are 9 medical groups, 106 transplantation doctors, and 320 nurses. Under the leadership of Dr Daopei Lu, our HSCT department performs 1/10 of the total transplant cases in China every year. From 2003 to 2022, the HSCT centre completed 9,757 cases, 4,664 cases are haplo-transplantation between relatives, 1,180 cases are unrelated transplantation, and 3,888 cases are other.
Number of Employees (Dec. 31, 2022)
|
Classification |
Number |
|
Doctors |
104 |
|
Nurses |
320 |
Department of BMT beds (Dec. 31, 2022）
|
Time |
LaminarFlowRooms |
GeneralBeds |
|
2022 |
162 |
1556 |
Number of BMT
Number of HSCT
As one of the most active HSCT centre, our HSCT department performs 1/10 of the total transplant cases in China every year.
From 2003 to 2022, the total number of HSCT cases was 9,757, including 4,664 cases of haploidentical (haplo) transplantation, 1,180 cases of unrelated donor (URD) transplantation.
Transplant Disease
Transplantation of diseases including blood cancer (leukemia, lymphoma, MDS, MDS/MPN, multiple myeloma, MPN etc.) and hematopoietic or immunodeficiency disease (aplastic anemia, PNH, Fanconi anemia, dyskeratosis congenita, hemophagocytic syndrome, hereditary immunodeficiency disease, congenital neutropenia, Mediterranean anemia etc.). The diseases could be treated by transplant include but not limited to the above.
Age of BMT
Minimum age of BMT: 2.5 months old.
Maximum age of BMT: 72 years old.
Advantage
We have the best outcomes in haploidentical and matched unrelated donor HSCT in the world. Moreover haplo-BMT in our hospital can achieve comparable outcomes with HLA-identical sibling transplantation.
BMT Overview
What is a blood and bone marrow transplant?
A blood and bone marrow transplant is a special type of treatment for people with certain types of cancer or other bone marrow disorders. In a blood and bone marrow transplant, cells normally found in the bone marrow are removed, processed and given back to the patient or another person. The aim of a blood and bone marrow transplant is to give a person healthy bone marrow cells after their own unhealthy bone marrow has been removed.
Blood and bone marrow transplants have been used successfully since 1968 to treat diseases such as leukaemia, lymphoma, aplastic anaemia, immunodeficiency disorders and some solid tumour cancers.
What is bone marrow?
Bone marrow is a semisolid tissue found inside the bones. It is the primary site for the production of new blood cells. All types of blood cells, including red blood cells, platelets and all types of white blood cells, are made by blood stem cells in the bone marrow. Bone marrow is not only a haematopoietic tissue, but also an important immune tissue. In order to perform a blood and bone marrow transplant, blood stem cells must be collected.
Why is a blood and bone marrow transplant necessary?
The aim of blood and bone marrow transplantation is to cure many haematological diseases. These include blood cancers, bone marrow failure (such as aplastic anaemia), some immunodeficiency diseases and so on. The risks and benefits of blood and bone marrow transplantation must be weighed up in a thorough discussion with your doctor and blood and bone marrow transplant specialists before the procedure.
For more information, see Bone marrow transplantation.
Conditions Treated
What diseases can benefit from a blood and bone marrow transplant?
The following diseases are the most common to benefit from blood and bone marrow transplantation:
·Immune deficiency diseases
While blood and bone marrow transplants can be curative for many people, patients experience diseases differently and blood and bone marrow transplants may not be appropriate for everyone with these diseases.
Common conditions treated include:
Acute leukaemia
Disease status:
·First, second or subsequent remission
·Induction failure
·Relapse
Type of transplant
·Allogeneic, related donor
·Allogeneic unrelated donor
Disease status:
·First, second or subsequent remission
·Induction failure
·relapse
Type of transplant
·Allogeneic, related donor
·Allogeneic, unrelated donor
Chronic leukaemias
Disease status:
·Chronic, accelerated or blast phase
Type of transplant
·Allogeneic, related donor
·Allogeneic, unrelated donor
Disease status:
· High-risk disease
·relapsed
Transplant type
·Allogeneic, related donor
·Allogeneic, unrelated donor
Lymphoma
Hodgkin's disease
Disease status:
- First or subsequent relapse
- Second or subsequent remission
- Failure to achieve a complete response
Type of transplant
·Autologous
·Allogeneic, related donor
·Allogeneic unrelated donor
Non-Hodgkin's lymphoma (NHL)
Disease status:
·First or subsequent relapse
·First remission in high risk disease
·Second or subsequent remission
·Failure to achieve a complete response
Type of transplant:
·Autologous
·Allogeneic, related donor
·Allogeneic unrelated donor
Plasma Cell Dyscrasias
Disease status:
·Stage I (select diseases)
·Stage II or III
·First or subsequent relapse
Type of transplant
·Autologous
Other haematological disorders
Aplastic anaemia (AA)
Type of transplant
·Allogeneic, related donor
·Allogeneic, unrelated donor
Myelodysplastic syndrome (MDS)
Transplant type:
·Allogeneic, related donor
·Allogeneic, unrelated donor
Myeloproliferative disorders (MPN)
Transplant type:
·Allogeneic, related donor
·Allogeneic, unrelated donor
Paroxysmal nocturnal haemoglobinuria (PNH)
Transplant type:
·Allogeneic, related donor
·Allogeneic unrelated donor
Haemophagocytic lymphohistiocytosis (HLH)
Transplant type:
·Allogeneic, related donor
·Allogeneic, unrelated donor
Thalassaemias
Type of transplant:
·Allogeneic, related donor
·Allogeneic, unrelated donor
Amyloidosis
Type of transplant
·Autologous
Waldenstrom's macroglobulinemia
Transplant type:
·Autologous
·Allogeneic, related donor
Types
Types of blood and bone marrow transplants
As well as providing expert clinical services during transplants, our hospital's medical staff also offer education and support to patients.
There are several types of blood and bone marrow transplants. The source of the haematopoietic (blood-forming) cells further defines the type of transplant. The haematopoietic cells used for transplantation can be taken from the blood or bone marrow. Haematopoietic cells, sometimes called blood stem cells, are immature cells that can divide and develop into any type of mature blood cell.
Blood and marrow transplants
Autologous transplant
In an autologous transplant, the conditioning regimen is given to treat your disease, but an infusion of your own haematopoietic (blood-forming) cells is needed to restore your body's ability to make blood cells. Your own blood-forming cells are collected and frozen before you receive the high-dose therapy. Your haematopoietic cells are given back to you as an infusion after the high-dose therapy. As with syngeneic transplants, there is no risk of rejection or graft-versus-host disease (GVHD), and there is no graft-versus-leukaemia (GVL) effect.
Allogeneic transplantation
An allogeneic donor is someone other than the patient. Allogeneic transplantation combines the concept of anti-cancer therapy with immunotherapy. The conditioning regimen is given to treat your disease, followed by an infusion of haematopoietic (blood-forming) cells from the blood or bone marrow of your donor. The donor cells provide you with new blood cells and a new immune system.
Allogeneic transplants have the lowest risk of tumour relapse due to the GVL effect. However, Graft-versus-Host Disease (GVHD), graft failure and immunodeficiency are potential problems.
Allogeneic donors are selected on the basis of a blood test for human leukocyte antigens (HLA). HLA are genetic markers of the immune system that allow each individual's immune cells to distinguish themselves from those of other people or foreign organisms. Donor cells are taken from an HLA matched (related or unrelated) or mismatched (related, at least 50% matched) individual. If the donor is related, the transplant is called a related donor blood and marrow transplant. If the donor is unrelated, the transplant is called an unrelated donor (URD) blood and marrow transplant.
The intensity of the conditioning regimen - the therapy given before you receive the donor cells - can vary. The intensity of the conditioning regimen ranges from high-dose preparative regimens to reduced intensity preparative regimens.
·HLA-matched unrelated donor transplant
·Haploidentical transplantation
Many patients who need a transplant do not have a matched family member or unrelated donor. Studies have shown that semi-identical, or haploidentical, related donor transplants can be performed with similar results to matched transplants. All parents and children, and about half of siblings, are half-matches. The ability to perform haploidentical transplants has revolutionised bone marrow transplantation, so that almost everyone who needs a transplant can now get one.
·Cord blood transplant
Syngeneic transplantation
The donor is the patient's identical twin. This is the simplest source of stem cells. Syngeneic transplants are the least complicated transplants because there is no risk of rejection, graft-versus-host disease (GVHD) or tumour in the bone marrow. Blood cell recovery and return of immune system function is rapid. The only disadvantage of syngeneic transplants is the lack of the graft-versus-leukaemia (GVL) effect of allogeneic transplants, which helps to reduce tumour relapse.
Treatment Process
·Before your visit, our staff will help you prepare for your visit.
·The table below gives a general overview of what to expect during your allogeneic bone marrow transplant (BMT).
• This chart is a general outline of what you can expect during your autologous transplant experience.